TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data
- Written by PR Newswire
![]() |
- The proceeds will fund its robust clinical programs and bolster TiumBio's financial position.
- Data read-outs from a Phase 2 trial of merigolix in endometriosis and a Phase 1b trial of TU2218 in solid tumors are expected in the first half of 2024
BOSTON and SEONGNAM, South Korea, Dec. 29, 2023 /PRNewswire/ -- TiumBio Co., Ltd. (KOSDAQ:...
Read more: TiumBio Secures KRW 38.5 Billion in Anticipation of Upcoming Clinical Data















